

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. VKSW/05	SERIAL NO. Unknown
		INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT Schlingensiepen et al.	10/567879
		(Use several sheets if necessary) (37 CFR 1.98(b))		FILING DATE February 12, 2006	GROUP Unknown

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A.A						
	A.B						
	A.C						
	A.D						
	A.E						
	A.F						
	A.G						
	A.H						
	A.I						
	A.J						
	A.K						

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
/TCG/	A.L	WO 01/68122	09/20/01	PCT	A61K	38/17	N/A
/TCG/	A.M	WO 99/65928	12/23/99	PCT	C07H	21/00	N/A
/TCG/	A.N	WO 99/50411	10/07/99	PCT	C12N	15/12	N/A
/TCG/	A.O	WO 2005/014812	02/17/05	PCT	C12N	15/11	N/A
	A.P						
	A.Q						

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

/TCG/	A.R	EPO, European Search Report, EP Application No. 03018285.1-2107, dated February 12, 2004
/TCG/	A.S	Golob et al, Characterization of a Transcription Factor Binding Site, Specifically Activating MIA Transcription in Melanoma, J Invest Dermatol 115:42-47, 2000
/TCG/	A.T	PCT, International Search Report, PCT Application No. PCT/EP2004/008986, mailed on March 29, 2005

EXAMINER	DATE CONSIDERED
/Terra Cotta Gibbs/	10/04/2007

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Not for submission under 37 CFR 1.99)</i>	Application Number		10567879
	Filing Date		2006-02-09
	First Named Inventor		Schlingensiepen
	Art Unit		1635
	Examiner Name		Terra C. Gibbs
	Attorney Docket Number		VKSW-05

U.S.PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button:

U.S.PATENT APPLICATION PUBLICATIONS						Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button:

FOREIGN PATENT DOCUMENTS							Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1							

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS							Remove
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.					T ⁵

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Not for submission under 37 CFR 1.99)</i>	Application Number	10567879
	Filing Date	2006-02-09
	First Named Inventor	Schlingensiepen
	Art Unit	1635
	Examiner Name	Terra C. Gibbs
	Attorney Docket Number	VKSW-05

/TCG/	1	Bogdahn, U. et al. / AUTOCRINE TUMOR CELL GROWTH-INHIBITING ACTIVITIES..... / CANCER RESEARCH, 1989. 49 (19): 5358-5363	<input type="checkbox"/>
	2	Weilbach, F.X. et al. / MELANOMA-INHIBITING ACTIVITY INHIBITS CELL..... CANCER RESEARCH, 1990. 50 (21): 6981-6986	<input type="checkbox"/>
	3	Blesch, A. et al. / CLONING OF A NOVEL MALIGNANT MELANOMA-DERIVED GROWTH-REGULATORY PROTEIN, MIA. / CANCER RESEARCH, 1994. 54(21): 5695-5701	<input type="checkbox"/>
	4	van Groningen, JJ, et al. / IDENTIFICATION OF MELANOMA INHIBITORY ACTIVITY AND OTHER DIFFERENTIALLY EXPRESSED.... / CANCER RESEARCH, 1995. 55(24): 6237-6243	<input type="checkbox"/>
	5	Bosserhoff, AK et al. / [MIA ("melanoma inhibitory activity"). Biological functions and clinical relevance in malignant melanoma]. Hautarzt, 1998. 49(10): 762-769	<input type="checkbox"/>
	6	Guba, M. et al. / OVEREXPRESSION OF MELANOMA INHIBITORY ACTIVITY (MIA) ENHANCES... / Br J Cancer, 2000. 83(9): 1216-1222	<input type="checkbox"/>
	7	Bosserhoff, AK et al. / FUNCTIONAL ROLE OF MELANOMA INHIBITORY ACTIVITY IN REGULATING INVASION AND METASTASIS OF MALIGNANT MELANOMA CELLS IN VIVO. / Melanoma Res, 2001. 11(4): 417-421	<input type="checkbox"/>
	8	STAHLCKER, J. et al. / MIA AS A RELIABLE TUMOR MARKER IN THE SERUM OF PATIENTS WITH MALIGNANT MELANOMA / Anticancer Res, 2000 20(6D): 5041-5044	<input type="checkbox"/>
	9	UHLMANN, E. et al. / ANTISENSE OLIGONUCLEOTIDES: A NEW THERAPEUTIC PRINCIPLE., Chemical Reviews, 1990. 90(4): 543-584	<input type="checkbox"/>
	10	GOODCHILD, J. / Conjugates of oligonucleotides and modified oligonucleotides: a review of their synthesis and properties. Bioconjug Chem, 1990. 1(3): 165-187	<input type="checkbox"/>
/TCG/	11	WAGNER, V. et al. / SEROPOSITIVITY FOR MIA AND S100 IN PATIENTS WITH GASTROINTESTINAL CARCINOMAS. / Med Oncol, 2000. 17(1): 35-38	<input type="checkbox"/>

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Not for submission under 37 CFR 1.99)</i>		Application Number	10567879
		Filing Date	2006-02-09
		First Named Inventor	Schlingensiepen
		Art Unit	1635
		Examiner Name	Terra C. Gibbs
		Attorney Docket Number	VKSW-05

/TCG/	12	NATSUME, N. et al. ANALYSIS OF CARTILAGE-DERIVED RETINOIC ACID-SENSITIVE PROTEIN.... / Spine, 2001. 26(2): 157-160	<input type="checkbox"/>
	13	BOSSERHOFF, AK et al. / MOUSE CD-RAP/MIA GENE: STRUCTURE, CHROMOSOMAL LOCALIZATION, AND EXPRESSION... / Dev Dyn, 1997. 208(4): 516-525	<input type="checkbox"/>
	14	MULLER-LADNER, U et al. / MIA (melanoma inhibitory activity): a potential serum marker for rheumatoid arthritis. / Rheumatology (Oxford), 1999. 38(2): 148-154	<input type="checkbox"/>
	15	BOSSERHOFF, AK et al. / IN SITU EXPRESSION PATTERNS OF MELANOMA-INHIBITING ACTIVITY.... J Pathology, 1999. 187(4): 446-454	<input type="checkbox"/>
	16	ZHAO, Q et al. / SITE OF CHEMICAL MODIFICATIONS IN CpG CONTAINING PHOSPHOROTHIOATE... Bioorg Medical Chem Lett, 1999. 9(24): 3453-3458	<input type="checkbox"/>
	17	SCARINGE, SA / RNA Oligonucleotide Synthesis via 5'-silyl-2-orthoester chemistry / Methods, 2001. 23(3): 206-217	<input type="checkbox"/>
↓/TCG/	18	FLAHERTY, KT et al. / ANTISENSE THERAPEUTICS: LESSONS FROM EARLY CLINICAL TRIALS... Curr Opin Oncol, 2001. 13(6): 499-505	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	/Terra Cotta Gibbs/	Date Considered	10/04/2007
--------------------	---------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.